FDA notes Medtronic device deaths
Wall Street Journal (subscription required), March 20, 2008
The Food and Drug Administration said it saw a higher death rate after five years among patients treated for abdominal aortic aneurysms with Medtronic Inc.'s AneuRx stent-graft system than among those treated through conventional surgery. The FDA said it was focusing on the AneuRx stent-graft system because it is the only currently marketed device that has a significant number of patients who have been followed for at least five years after receiving a device.
- mHealth Tackles Readmissions
- 'Kafkaesque' Value System Unfairly Penalizes Doctor Pay
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Targeting Self-Insured Populations
- MA an Insurance Proving Ground for Providers
- Proton Beam Therapy Poised for Growth in US
- Sharp HealthCare Leaves Pioneer ACO Program
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Docs Fret as HHS Addresses Malpractice Reporting 'Loopholes'